

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

P

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A01N 43/04, A61K 31/70	A1	(11) International Publication Number: <b>WO 00/11952</b>
		(43) International Publication Date: 9 March 2000 (09.03.00)

(21) International Application Number: PCT/US99/19725

(22) International Filing Date: 31 August 1999 (31.08.99)

(30) Priority Data:  
09/144,096 31 August 1998 (31.08.98) US(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application  
US 09/144,096 (CIP)  
Filed on 31 August 1998 (31.08.98)(71) Applicant (for all designated States except US):  
PRO-NEURON, INC. [US/US]; 16020 Industrial Drive,  
Gaithersburg, MD 20877 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): VON BORSTEL, Reid, W.  
[US/US]; 8310 Fox Run, Potomac, MD 20854 (US).(74) Agent: BYRNE, Thomas, E.; Nixon & Vanderhye P.C., Suite  
800, 1100 North Glebe Road, Arlington, VA 22201-4714  
(US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published***With international search report.*

(54) Title: COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES

## (57) Abstract

Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidien nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies.